Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidance Needed On Internal Tissue Adhesives, FDA And Industry Agree

This article was originally published in The Gray Sheet

Executive Summary

Based on discussions at a recent workshop, FDA sees "multiple opportunities for guidance" on internal tissue adhesives, an agency official said.

You may also be interested in...



FDA To Internal Tissue Adhesive Firms: Come In Early With Details

Device firms developing new internal tissue adhesive products should meet with the agency early on and provide detailed descriptions of their product and clinical protocol, agency officials said at a recent meeting.

FDA To Internal Tissue Adhesive Firms: Come In Early With Details

Device firms developing new internal tissue adhesive products should meet with the agency early on and provide detailed descriptions of their product and clinical protocol, agency officials said at a recent meeting.

FDA Reclassifications In Brief

Digital mammography: FDA 1proposes May 30 to downclassify full field digital mammography systems from Class III to Class II, following the 2006 recommendation of its Radiological Devices Panel (2"The Gray Sheet" May 29, 2006, p. 6). The agency also released a special controls 3draft guidance outlining proposed electrical safety and physical laboratory 510(k) testing requirements. Comments on the proposed reclassification and draft guidance are due Aug. 29

Related Content

Topics

UsernamePublicRestriction

Register

MT030584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel